CD8A and neoplasm: We could not observe tumor growth advantage in B16F10-bearing C57BL/6 mice with murine IL-15 treatment; it likely due to the expansion and activation of CD8+ T cells upon murine IL-15 treatment (Figures S3A–D in Supplementary Material).